ClinicalTrials.gg

Program

MMH-407

A development code. Also written as “Raphamin”.

Its studies are mostly in Bronchitis · Rhinosinusitis · Cystitis · Community-Acquired Pneumonia · COVID-19, led by Materia Medica.

Furthest: phase 3, since Dec 13, 20199 company-led studies, 4 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Materia Medica94 open or runningphase 3since Dec 13, 2019Dec 13, 2019Dec 31, 2026phase 3 · NCT06284265

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 13, 2019First study: phase 3 study in Viral Respiratory InfectionFirst studyNCT04244084 · 240 enrolled · Russian Federation
  2. Jan 29, 2020Phase 3 study in Influenza, HumanNCT04250311 · 314 enrolled · Russian Federation
  3. May 21, 2021Phase 3 study in Acute Respiratory Viral InfectionNCT04918771 · 435 enrolled · Russian Federation
  4. May 4, 2022Phase 3 study in COVID-19NCT05364671 · 771 enrolled · Russia
  5. Feb 9, 20242 phase 3 studiesNCT06263881, NCT06284265
  6. Nov 29, 2024Phase 3 study in Acute Respiratory Viral InfectionNCT06715891 · 374 planned · Russia
  7. Mar 24, 2025Phase 3 study in RhinosinusitisNCT06901297 · 552 planned · Russia
  8. Jun 10, 2026Phase 3 study in BronchitisNCT07650227 · 308 planned · Russia

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Cystitis ChronicNCT06284265
  2. Dec 31, 2027Primary completion: phase 3 study in RhinosinusitisNCT06901297
  3. Dec 31, 2027Primary completion: phase 3 study in Acute Respiratory Viral InfectionNCT06715891
  4. Dec 31, 2028Primary completion: phase 3 study in BronchitisNCT07650227

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07650227Bronchitis · Russia3RecruitingDec 31, 2028308
NCT06901297Rhinosinusitis · Russia3RecruitingDec 31, 2027552
NCT06715891Acute Respiratory Viral Infection · Russia3RecruitingDec 31, 2027374
NCT06284265Cystitis Chronic · Russia3Active, not recruitingDec 31, 2026415
NCT06263881Community-Acquired Pneumonia · Russian Federation3CompletedMar 19, 2025370
NCT05364671COVID-19 · Russia3CompletedAug 18, 2023771
NCT04918771Acute Respiratory Viral Infection · Russian Federation3CompletedJul 21, 2023435
NCT04250311Influenza, Human · Russian Federation3SuspendedDec 2024314
NCT04244084Viral Respiratory Infection · Russian Federation3CompletedApr 9, 2020240

How it is read

Names in the registry

  • “Raphamin”, 7 entries
  • “MMH-407”, 2 entries

Codes read as this program: MMH407.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.